Inspire Medical Systems, Inc. Share Price

Equities

INSP

US4577301090

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 16:25:19 16/07/2024 BST 5-day change 1st Jan Change
144.6 USD +4.33% Intraday chart for Inspire Medical Systems, Inc. +9.94% -28.96%
Sales 2024 * 788M 60.84B Sales 2025 * 949M 73.24B Capitalization 4.12B 318B
Net income 2024 * 5M 386M Net income 2025 * 27M 2.08B EV / Sales 2024 * 4.68 x
Net cash position 2024 * 430M 33.22B Net cash position 2025 * 530M 40.96B EV / Sales 2025 * 3.78 x
P/E ratio 2024 *
843 x
P/E ratio 2025 *
162 x
Employees 1,011
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.02%
More Fundamentals * Assessed data
Dynamic Chart
Truist Cuts Price Target on Inspire Medical Systems to $217 From $280, Maintains Buy Rating MT
Morgan Stanley Cuts Price Target on Inspire Medical Systems to $210 From $250, Keeps Overweight Rating MT
ANALYST RECOMMENDATIONS : Citigroup, Constellation Brands, Broadcom, JPMorgan, Bunzl... Our Logo
Shares of ResMed, Inspire Medical Down After Eli Lilly Provides Sleep Apnea Study Update DJ
Stifel Adjusts Price Target on Inspire Medical Systems to $170 From $210, Maintains Hold Rating MT
RBC Cuts Price Target on Inspire Medical Systems to $260 From $285, Maintains Outperform Rating MT
Transcript : Inspire Medical Systems, Inc. Presents at 2024 Truist Securities MedTech Conference, Jun-18-2024 10:40 AM
Transcript : Inspire Medical Systems, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 11:30 AM
Transcript : Inspire Medical Systems, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM
Top Premarket Decliners MT
Transcript : Inspire Medical Systems, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (INSP) INSPIRE MEDICAL SYSTEMS Posts Q1 Revenue $164M, vs. Street Est of $161.1M MT
Inspire Medical Systems Q1 Loss Narrows, Revenue Rises; Full-Year Revenue Outlook Raised -- Shares Slump After Hours MT
Inspire Medical Systems, Inc. Revises Financial Guidance for the Full Year 2024 CI
Inspire Medical Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
More news
1 day+4.30%
1 week+9.94%
Current month+7.98%
1 month-11.71%
3 months-34.80%
6 months-22.35%
Current year-28.96%
More quotes
1 week
130.50
Extreme 130.5
145.32
1 month
129.95
Extreme 129.95
173.78
Current year
129.95
Extreme 129.95
257.40
1 year
123.27
Extreme 123.27
328.70
3 years
123.27
Extreme 123.27
330.00
5 years
40.53
Extreme 40.53
330.00
10 years
22.50
Extreme 22.5
330.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 31/10/07
Director of Finance/CFO 56 15/05/14
Chief Tech/Sci/R&D Officer 61 27/07/22
Members of the board TitleAgeSince
Director/Board Member 66 24/07/19
Director/Board Member 64 30/06/08
Director/Board Member 66 31/12/07
More insiders
Date Price Change Volume
16/07/24 144.5 +4.26% 108 304
15/07/24 138.6 -0.22% 504,127
12/07/24 138.9 +2.40% 361,241
11/07/24 135.6 +3.25% 535,955
10/07/24 131.4 -0.06% 448,055

Delayed Quote Nyse, July 16, 2024 at 04:10 pm

More quotes
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The Company has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sell its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ENT physicians and sleep centers.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
138.6 USD
Average target price
237.7 USD
Spread / Average Target
+71.55%
Consensus